Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51. Six and 12 month results of a multicenter follow-up phase 3 study

Vaccine

Volumn 26, Issue 34, 2008, Pages 4382-4386

  Schuller, E ^a   Jilma, B ^b   Voicu, V ^c   Golor, G ^d   Kollaritsch, H ^b   Kaltenbock A ^a   Klade, C ^a   Tauber, E ^a  

^a INTERCELL AG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Institutul National de Medicina Aeronautica si Spatiala   (Romania)

^d PAREXEL INTERNATIONAL   (United States)

Author keywords

Japanese encephalitis; Vaccine; Virus

Indexed keywords

IC 51; INACTIVATED VIRUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; JE-VAX; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MALE; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SEROCONVERSION; VERO CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, VIRAL; ASIA; CERCOPITHECUS AETHIOPS; DOUBLE-BLIND METHOD; ENCEPHALITIS VIRUS, JAPANESE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TIME FACTORS; VACCINES, INACTIVATED; VERO CELLS;

EID: 47849106825     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.081     Document Type: Article

References (25)

1. Burke D.S., and Leake C.J. Japanese encephalitis. In: Monath T.P. (Ed). The arboviruses: epidemiology and ecology vol. III (1988), CRC Press, Boca Raton, FL 63-92
2. Vaughn D.W., and Hoke C.H. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 14 (1992) 197-221
3. Shlim D.R., and Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 352 (2002) 183-188
4. Tourism Market Trends 2004: Asia and the Pacific. 2004 ed.. World Travel Organization (WTO). Published 11 July 2005.
5. Bista M.B., Banerjee M.K., Shin S.H., Tandan J.B., Kim M.H., Sohn Y.M., et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358 (2001) 791-795
6. Hennessy S., Liu Z., Tsai T.F., Strom B.L., Wan C.M., Liu H.L., et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347 (1996) 1583-1586
7. Ohrr H., Tandan J.B., Sohn Y.M., Shin S.H., Pradhan D.P., and Halstead S.B. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366 (2005) 1375-1378
8. Tsai T.F. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 18 Suppl. 2 (2000) 1-25
9. Andersen M.M., and Rønne T. Side-effects with Japanese encephalitis vaccine. Lancet 337 (1991) 1044
10. Japanese Encephalitis Vaccine and Adverse Effects among Travelers. Canada Diseases Weekly Report. 1991;17-32:173-7.
11. Ruff T.A., Eisen D., Fuller A., and Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 338 (1991) 881-882
12. GACVS. Weekly epidemiological record No 28, 2005, 80, 241-8. Available at: http://www.who.int/wer/2005/wer8028.pdf. Accessed 30 April 2008.
13. Lyons A., Kanesa-thasan N., Kuschner R.A., Eckels K.H., Putnak R., Sun W., et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25 (2007) 3445-3453
14. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370 (2007) 1847-1853
15. Kaltenboeck A., Beckett C., Firbas C., Jelinek T., Knobloch J., Lyons A., et al. Safety and tolerability of the Japanese encephalitis vaccine IC51. A double-blind, randomized, placebo controlled phase 3 study. Oral presentation at conference of the international society of travel medicine, May 20-24. Vancouver, Canada (2007)
16. 14-14-2: adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 6 (1988) 513-518
17. Srivastava A.K., Putnak J.R., Lee S.H., Hong S.P., Moon S.B., Barvir D.A., et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19 (2001) 4557-4565
18. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18 Suppl. 2 (2000) 26-32
19. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23 (2005) 5205-5211
20. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1993; 42(No. RR-1):1-14.
21. DeFraites RF. Immunogenicity and safety of Japanese encephalitis vaccine (inactivated: Nakayama/BIKEN) in U.S. Army soldiers: evaluation of three consecutively manufactured lots of vaccine administered in two dosing regimens. April 30, 1991 and November 12, 1992. Unpublished data, on file with BIKEN and with the Walter Reed Army Institute of Research, Washington, D.C.
22. Sukhavachana P., Yuill T.M., and Russell P.K. Assay of arbovirus neutralizing antibody by micro methods. Trans R Soc Trop Med Hyg 63 (1969) 446-455
23. Altman DG, Leake CJ, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence. 2nd ed. Bristol: BMJ Books; 2000.
24. DeFraites R.F., Gambel J.M., Hoke C.H., Sanchez J.L., Withers B.G., Karabatsos N., et al. Japanese encephalitis vaccine (inactivated BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg 61 (1999) 288-293
25. Sanchez J.L., Hoke C.H., McCown J., DeFraites R.F., Takafuji E.T., Diniega B.M., et al. Further experience with Japanese encephalitis vaccine. Lancet 335 (1990) 972-973